Cell therapy (CAR-T) · Kills target cells, directed at CD22 · developed by Cellectis
Lasmecabtagene timgedleucel is an allogeneic, off-the-shelf T-lymphocyte cell therapy engineered with TALEN gene editing to express a chimeric antigen receptor targeting CD22. The CAR-expressing cells bind CD22 on tumor cells, leading to lysis of CD22-expressing cells. It is being studied in B-cell acute lymphoblastic leukemia.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT04150497 | Phase 1/2 | B-cell Acute Lymphoblastic Leukemia | Recruiting | CLLS |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
B-cell Acute Lymphoblastic Leukemia
Updated Oct 11, 2026. Something wrong or missing? Report it on the CLLS page.
See CLLS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
CLLS catalysts and pipeline →